Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.

The combination may become the "new go-to option" for women with PIK3CA-mutated hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, said the ...

PIK3CA mutations are found in 35-40% of HR+ breast cancers. The three-drug therapy of inavolisib, palbociclib and fulvestrant is not approved in the UK. However, the combination of palbociclib and ...

A new three-drug combination could help women with a common form of aggressive breast cancer live longer, research suggests. The treatment could also delay the need for gruelling chemotherapy, ...

Combating treatment resistance The new drug, inavolisib works by blocking the activity of the PIK3CA protein. However, it also has a second mode of action which triggers the breakdown of the mutated ...

John Wang received his Ph.D. in Microbiology from University of Virginia in 2001. He was a postdoctoral fellow with Dr. Bert Vogelstein in the Sydney Kimmel Comprehensive Cancer Center at Johns ...

The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17%. AstraZeneca is discontinuing the late-stage CAPItello-280 trial, which ...

But, Dr. Young added, even people using GLP-1 drugs need only a fraction more protein than the recommended amount for an adult, which is 0.8 grams of protein per kilogram of body weight per day.

Dr. Wang co-discovered that PIK3CA, which encodes p110α catalytic subunit of PI3 kinase, is frequently mutated in human cancers. His laboratory recently found that PIK3CA mutations render colorectal ...

PROS is a group of rare genetic conditions that result from variations in the PIK3CA gene. This gene produces a protein that helps regulate how cells grow, survive, and divide. Mutations in this ...

Yuxiang Wang, Valery Rozen, Yiqing Zhao, Zhenghe Wang, Oncogenic activation of PIK3CA in cancers: Emerging targeted therapies in precision oncology, Genes & Diseases, Volume 12, Issue 2, 2025 ...

In a nutshell Researchers discovered how a specific genetic mutation (PIK3CA) changes the way blood vessel cancers grow and evade the immune system in both dogs and humans, potentially leading to new ...